 |
 | This article may contain excessive or inappropriate references to self-published sources .(October 2016) |
 | |
| Company type | Private Limited Company |
|---|---|
| Industry | Pharmaceuticals |
| Founded | 2015 |
| Founder | Professor David Haddleton |
| Headquarters | Coventry , United Kingdom |
| Website | Official website |
Medherant Ltd is a British pharmaceutical company, based in Coventry. The company is developing over-the-counter (OTC) and prescription transdermal patches for drug delivery.
Medherant Ltd was founded as a university spin-off by Professor David Haddleton and the University of Warwick in 2015 for the purpose of commercialisation of a novel drug delivery system. Started as a research project in Haddleton Group at the University of Warwick in 2013, the company operates at the University of Warwick Science Park since March 2015 after securing an investment from the Mercia Fund Management in 2014 and has received over £15M investment by the end of 2025.
Using its research in polyurea based pressure sensitive adhesives [1] and polymer chemistry, the company is working to introduce transdermal drug delivery patches via the transepidermal route. [2] Medherant's TEPI patch technology aims to provide controlled delivery of the correct dose, and better patient experience. The technology is also designed to be environmentally and economically efficient, requiring no solvents for the fabrication process. [3]
Medherant is currently (2025) in clinical trials with a testosterone for postmenopausal women [4] which has shown excellent results to date. [5] Medherant has also been developing transdermal analgesic patches for pain relief, based on nonsteroidal anti-inflammatory drugs (NSAIDs), e.g. ibuprofen, lidocaine, diclofenac and methyl salicylate.